- Home
- IBTA vs COGT Comparison
IBTA vs COGT Comparison
Compare IBTA & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- COGT
- Stock Information
- Founded
- IBTA 2011
- COGT 2014
- Country
- IBTA United States
- COGT United States
- Employees
- IBTA N/A
- COGT N/A
- Industry
- IBTA
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- COGT Health Care
- Exchange
- IBTA Nasdaq
- COGT Nasdaq
- Market Cap
- IBTA 892.4M
- COGT 1.1B
- IPO Year
- IBTA 2024
- COGT 2018
- Fundamental
- Price
- IBTA $40.05
- COGT $12.07
- Analyst Decision
- IBTA Buy
- COGT Strong Buy
- Analyst Count
- IBTA 10
- COGT 9
- Target Price
- IBTA $74.60
- COGT $20.25
- AVG Volume (30 Days)
- IBTA 369.9K
- COGT 5.1M
- Earning Date
- IBTA 08-13-2025
- COGT 08-05-2025
- Dividend Yield
- IBTA N/A
- COGT N/A
- EPS Growth
- IBTA 24.66
- COGT N/A
- EPS
- IBTA 2.03
- COGT N/A
- Revenue
- IBTA $369,501,000.00
- COGT N/A
- Revenue This Year
- IBTA $6.89
- COGT N/A
- Revenue Next Year
- IBTA $15.55
- COGT N/A
- P/E Ratio
- IBTA $19.69
- COGT N/A
- Revenue Growth
- IBTA 7.20
- COGT N/A
- 52 Week Low
- IBTA $31.40
- COGT $3.72
- 52 Week High
- IBTA $79.80
- COGT $12.97
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- COGT 78.82
- Support Level
- IBTA N/A
- COGT $11.93
- Resistance Level
- IBTA N/A
- COGT $12.79
- Average True Range (ATR)
- IBTA 0.00
- COGT 0.74
- MACD
- IBTA 0.00
- COGT 0.03
- Stochastic Oscillator
- IBTA 0.00
- COGT 76.56
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.